ResMed Inc. (NYSE:RMD) Stock Holdings Raised by Elo Mutual Pension Insurance Co

Elo Mutual Pension Insurance Co raised its holdings in shares of ResMed Inc. (NYSE:RMD) by 17.4% in the 4th quarter, Holdings Channel reports. The firm owned 15,229 shares of the medical equipment provider’s stock after purchasing an additional 2,261 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in ResMed were worth $3,483,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. True Wealth Design LLC grew its position in ResMed by 2,200.0% in the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 110 shares during the last quarter. OFI Invest Asset Management acquired a new stake in shares of ResMed during the fourth quarter worth $39,000. BankPlus Trust Department purchased a new stake in ResMed during the fourth quarter valued at about $44,000. Rosenberg Matthew Hamilton acquired a new position in ResMed in the 4th quarter worth approximately $54,000. Finally, SBI Securities Co. Ltd. purchased a new position in shares of ResMed during the fourth quarter valued at $67,000. Institutional investors own 54.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on RMD shares. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a report on Tuesday. UBS Group upgraded shares of ResMed from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 31st. KeyCorp raised their target price on ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a report on Friday, January 31st. JPMorgan Chase & Co. boosted their price objective on shares of ResMed from $270.00 to $286.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Finally, Stifel Nicolaus cut their target price on ResMed from $250.00 to $240.00 and set a “hold” rating for the company in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $249.73.

ResMed Stock Performance

Shares of NYSE:RMD opened at $219.85 on Friday. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The firm has a market cap of $32.29 billion, a PE ratio of 25.96, a PEG ratio of 1.53 and a beta of 0.74. The company’s 50 day moving average price is $233.70 and its two-hundred day moving average price is $238.23. ResMed Inc. has a 12-month low of $172.19 and a 12-month high of $263.05.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. Equities research analysts predict that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th were given a $0.53 dividend. The ex-dividend date of this dividend was Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.96%. ResMed’s dividend payout ratio (DPR) is presently 25.03%.

Insider Buying and Selling at ResMed

In other news, insider Kaushik Ghoshal sold 9,745 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the transaction, the insider now owns 9,725 shares of the company’s stock, valued at $2,327,289.75. This represents a 50.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the sale, the director now directly owns 77,218 shares of the company’s stock, valued at approximately $18,695,249.98. The trade was a 2.52 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,940 shares of company stock valued at $9,164,385. 0.71% of the stock is currently owned by company insiders.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.